Track topics on Twitter Track topics that are important to you
Innovation and Clinical Trial Tracking Factbook 2017: An Assessment of the Pharmaceutical Pipeline
GBI Research's latest report, Innovation and Clinical Trial Tracking Factbook 2017: An Assessment of the Pharmaceutical Pipeline is a comprehensive, granular analysis of the 25,522 products currently in the pharmaceutical industry pipeline, from the Discovery stage through to Preregistration and split into therapy areas and key indications. This pipeline is also benchmarked against its size across each segment compared to 2015 and 2016, and an assessment of the level of firstinclass innovation is provided. In addition, a detailed contextual analysis of the key drivers of this pipeline is provided, in addition to an assessment of companies present in the pipeline and historical deal value and volume.
Innovation, particularly the development of new products, is a crucial element of the pharmaceutical industry. The market is highly researchintensive, being deeply reliant on a high level of RD investment and a strong product pipeline to maintain growth and ensure longterm revenue generation. Without successful innovation, which can be broadly defined as the market launch of novel therapeutic molecules that costeffectively treat or cure diseases, the industry would face a substantial longterm decline in revenue.
A particular focus of this report is placed on analysis of the development of innovative drugs, specifically firstinclass innovation. Over recent decades, in addition to an increase in the yearly number of new chemical entity approvals by the FDA, the number and proportion of these approvals that were firstinclass at the time of approval have also increased. The proportion of firstinclass approvals has increased steadily each year since 1994, with the exception of the years 20052008, when the proportion was relatively high.
What is the current size and composition of the pharmaceutical industry pipeline and how has it changed in the last two years? What can we learn from this?
The largest therapy area, by a substantial margin, is oncology, and, with growth in the pipeline sizes for all major oncology indications since Q1 2015, this trend appears set to continue. Why is this the case?
What is the overall advantage for companies including firstinclass product developments in their pipeline portfolio, rather than opting for bettercharacterized established molecular targets?
What factors have been driving the increasing number of firstinclass product approvals over recent decades?
Historically, what has the risk of clinical trial attrition been across each therapy area and molecule type in the pharmaceutical industry?
How long have their associated clinical trials been and how many patients, on average, were recruited?
Key Reasons to Purchase
Achieve an uptodate understanding of the landscape of the overall pharmaceutical pipeline, on both a broad and granular level; this also provides a highly accessible reference which is useful in any pharmaceutical strategic decision making process
Benchmark key therapy areas and indications in terms of the number of pipeline products and level of innovation, and assess one's own strategic positioning against this backdrop
Understand the contemporary role and importance of radical and incremental innovation within the various disease areas and indications
Make key decisions about the role of innovation within one's own pipeline portfolio
Understand and benchmark the risk of attrition, clinical trial duration and size across the pharmaceutical industry
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...